NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $36.75 Average Target Price from Brokerages

by · The Markets Daily

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Get Free Report) has earned a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $36.75.

Several brokerages have recently commented on NRXP. BTIG Research restated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Zacks Research cut NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday, January 21st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, February 17th.

View Our Latest Stock Analysis on NRx Pharmaceuticals

Institutional Trading of NRx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. One Wealth Management Investment & Advisory Services LLC grew its position in NRx Pharmaceuticals by 35.3% during the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after buying an additional 9,882 shares during the period. State Street Corp grew its holdings in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after buying an additional 10,700 shares in the last quarter. Ethos Financial Group LLC bought a new stake in NRx Pharmaceuticals during the 3rd quarter worth approximately $39,000. Sjbenen Advisory LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth $41,000. Finally, Two Sigma Investments LP raised its holdings in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Trading Up 1.3%

NRXP stock opened at $1.91 on Friday. The firm has a market capitalization of $60.87 million, a PE ratio of -0.81 and a beta of 1.91. The business’s 50 day simple moving average is $2.16 and its 200 day simple moving average is $2.53. NRx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $3.84.

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

Featured Stories